In addition, levels of GPR84 expression are significantly upregulated in human and mouse AML LSCs compared to normal HSCs [83], providing a therapeutic window to selectively target LSCs while sparing normal HSCs. This evidence concerns the gene GPR84 and acute myeloid leukemia.